Cagrilintide (± CagriSema) vs Tirzepatide (Mounjaro / Zepbound)
Both are used for gut health. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| Cagrilintide (± CagriSema) | Tirzepatide (Mounjaro / Zepbound) | |
|---|---|---|
| Human evidence | ★★★★☆ | ★★★★★ |
| Legal status | Not Approved | Prescription |
| How it works | Long-acting amylin receptor (CALCR/RAMP) agonist; amylin slows gastric emptying and enhances satiety through a pathway complementary to GLP-1. CagriSema (cagrilintide + semaglutide) targets ~25% weight loss. | Dual agonist of GIPR (GIP receptor) and GLP1R. GIP receptor activation in the hypothalamus and adipose tissue synergises with GLP-1, producing greater appetite suppression and fat loss than GLP-1 alone. |
| In plain English | A second gut-fullness hormone (amylin) stacked on top of GLP-1 — two different "I'm full" systems for bigger appetite suppression. | Hits two "I'm full" gut-hormone switches at once instead of one — so it works even better. SURMOUNT-1: 22.5% bodyweight lost, approaching bariatric-surgery territory. |
| Bottom line | The likely next combo blockbuster; investigational. | Currently the most effective approved obesity drug. |
| Availability | Not widely approved | Prescription only |
Which is better for gut health?
Tirzepatide (Mounjaro / Zepbound) has the stronger human-evidence rating (★★★★★ vs ★★★★☆), but the right choice still depends on your goal, tolerance and budget.
Full breakdowns: Cagrilintide (± CagriSema) · Tirzepatide (Mounjaro / Zepbound).
Common questions
Is Cagrilintide (± CagriSema) or Tirzepatide (Mounjaro / Zepbound) better for gut health?
Tirzepatide (Mounjaro / Zepbound) has the stronger human-evidence rating (★★★★★ vs ★★★★☆), but the right choice still depends on your goal, tolerance and budget.
What's the difference between Cagrilintide (± CagriSema) and Tirzepatide (Mounjaro / Zepbound)?
Cagrilintide (± CagriSema): The likely next combo blockbuster; investigational. — Tirzepatide (Mounjaro / Zepbound): Currently the most effective approved obesity drug.